Onclive Team

Although gemcitabine-based chemotherapy is standard in advanced pancreatic cancer, the role of adjuvant chemotherapy is still incompletely defined.

Clinical investigations of tremelimumab in melanoma were the focus of several presentations at ASCO.

In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).

For patients undergoing chemotherapy, one of the greatest challenges they face is enduring what can be a grueling treatment regimen. Optimal nutrition can help patients better cope with the rigors of chemotherapy.

A new study shows that less than one half of older patients successfully treated for colorectal cancer receive the recommended screening schedule to detect any recurrence of cancer. The analysis indicates poor compliance with recommended monitoring of colorectal cancer survivors could affect survival.

The 10th Annual Meeting of the World Congress on Gastrointestinal Cancer was held in Barcelona, Spain, in June. The Congress has grown into a key scientific program that covers malignancies affecting every component of the gastrointestinal tract and all facets of patient care, including screening, diagnosis, and management options for common and uncommon tumors.

The International Liver Cancer Association (ILCA) takes a multidisciplinary approach to furthering the understanding and management of hepatocellular carcinoma (HCC). In September 2008, researchers from more than 40 countries attended the Second Annual Conference in Chicago, Illinois to discuss the most recent findings on diagnosis and treatment.

On January 12, 2010, a 7.0-magnitude earthquake rocked Haiti, the poorest country in the Western Hemisphere, for 35 to 40 seconds.The island country's capital of Port-au-Prince was hardest hit, with heavy damage to buildings and infrastructure and major loss of life.

The potential federal healthcare overhaul engendered a bitter debate over rumored "death panels" making end-of-life decisions for patients. Although the claims were never substantiated, the furor directed the nation's attention to the important issue of end-of-life care.

Although the latest supply and demand data for oncologists reflect a state of relative equilibrium, analysis of patient-visit data projects a shortage of thousands of oncologists by 2020.

There is great disparity in outcomes between whites and blacks in the United States. Find out how these numbers add up in By The Numbers.

At the Third Annual Interdisciplinary Prostate Cancer Congress in March, the audience viewed presentations of real prostate cancer cases treated by the speakers. How would you treat the patient in this case study? Compare your responses with those of the attendees and the expert panel.

Healthcare professionals and patients are facing a longer wait for the FDA to approve generic drugs than they were just 5 years ago--1 year longer, in fact. The delayed approval process is due to a growing backlog of applications at the FDA.

Ramucirumab is an investigational immunoglobin G1 (IgG1) monoclonal antibody (mAb) currently under development. It uses only human cells, allowing it to avoid many of the adverse effects associated with murine or chimeric mAbs. Ramucirumab binds to human VEGFR-2, thus blocking VEGF binding and thwarting the angiogenic process.

Capsule summaries of current issues and developments in breast cancer, kidney disease, supportive care, and melanoma are presented, as well as timely updates on FDA actions and approvals.

A selection of essays and articles that discusses such issues as breast cancer screening recommendations, the oncologist's role in how mass media reports about cancer, patients' increased risk of cancer from CT scans, insomnia in cancer patients, and the association of advanced care planning with more practical coping skills in patients with hematologic malignancies.